Stellar Pharmaceuticals Schedules Fourth Quarter And Year-End Financial Results And Conference Call.LONDON -- Stellar Pharmaceuticals, Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SLXCF)(TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:SLX SLX Student Loan Xpress SLX Smartlet Xml SLX Secure Links SLX Super Luxe ), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it plans to release its 2004 fourth quarter and year-end financial results prior to the opening of the stock market on Thursday, March 31, 2005. Management will conduct a conference call later that morning at 11:00 a.m. Eastern Time to discuss these results. Interested parties may participate in the call by dialing 877-888-3490 (Domestic) or 416-695-5261 (International) approximately 10 minutes before the call is scheduled to begin and ask to be connected to the Stellar Pharmaceuticals Conference Call. The call will also be simultaneously broadcast over the Internet. Those interested in listening to the live webcast may do so by going to the Company's website at www.stellarint.com or by going to http://events.onlinebroadcasting.com/stellar/033105/index.php. Web participants are encouraged to go to either website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archive will be available immediately after the live call and continue for approximately 30 days. About Stellar Pharmaceuticals Stellar Pharmaceuticals Inc. has developed and is marketing three products in Canada based on its core polysaccharide technology: NeoVisc(R), for the treatment of osteoarthritis, Uracyst(R) and the Uracyst(R) Test Kit, Stellar's patented technology for the diagnosis and treatment of Interstitial Cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreements for Skelite(TM), a proprietary synthetic bone-grafting product and NMP NMP New Millennium Program (NASA) NMP National Military Park (National Park Service) NMP N-Methylpyrrolidone NMP Network Management Protocol NMP Not My Problem 22(R) BladderChek(R), a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer which are expected to positively impact sales in 2005. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed time to time in the Company's filings. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Stellar Pharmaceuticals Inc. (TSX VENTURE:SLX) (OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. :SLXCF) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion